Trial · NCT02005029
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Gastric Emptying Time | 2 weeks, between visits 2 and 3 | Of the original ten participants; one participant's data was excluded due to symptomatic orthostasis which likely confounded her results, one participant was withdrawn early due to noncompliance, and four participants were unable to complete a SmartPill evaluation. | minutes | MEAN |
| PRIMARY | Area Under the Curve 0-4 Hours for Plasma Levodopa After Erythromycin Versus Placebo | 2 weeks, between visits 2 and 3 | Of the original ten participants; one participant's data was excluded due to symptomatic orthostasis which likely confounded her results, one participant was withdrawn early due to noncompliance, and one participant had undetectable plasma levodopa levels through out the study and was thus excluded from the pharmacokinetic analysis. | ng/mL*min | MEAN |
| SECONDARY | 9-hole Peg Test Right Hand | 2 weeks, between visits 2 and 3 | Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance. | seconds | MEAN |
| SECONDARY | 9-hole Peg Test Left Hand | 2 weeks, between visits 2 and 3 | Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance. | seconds | MEAN |
| SECONDARY | Five Times Sit-to-stand Test | 2 weeks, between visits 2 and 3 | Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance. | seconds | MEAN |
| SECONDARY | Comfortable 20 Feet Gait Speed (CGS) | 2 weeks, between visits 2 and 3 | Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance. | seconds | MEAN |
| SECONDARY | Timed up and go Test (TUAG) Comfortable Speed | 2 weeks, between visits 2 and 3 | Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance. | seconds | MEAN |
| SECONDARY | Timed up and go Test (TUAG) Fast Speed | 2 weeks, between visits 2 and 3 | Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance. | seconds | MEAN |
| SECONDARY | Change in Dyskinesia | 2 weeks, between visits 2 and 3 | Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance. | units on a scale | MEAN |
| SECONDARY | MDS-UPDRS Part 3 (Movement Disorders Society- Unified Parkinson's Disease Rating Scale) | 2 weeks, between visits 2 and 3 | One participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance. | units on a scale | MEAN |
| SECONDARY | Mean Cmax of Plasma Levodopa After Erythromycin Versus Placebo | 2 weeks, between visits 2 and 3 | Of the original ten participants; one participant's data was excluded due to symptomatic orthostasis which likely confounded her results, one participant was withdrawn early due to noncompliance, and one participant had undetectable plasma levodopa levels throughout the study and was thus excluded from the pharmacokinetic analysis. | ng/mL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02005029/outcomes